WALTHAM, Mass.--(BUSINESS WIRE)--April 26, 2006--Company Highlights First Quarter Accomplishments, Including:
Initiation of a Phase II Clinical Trial in the United States in Stage IIIa/IIIb Non Small Cell Lung Cancer (NSCLC)
Completion of Patient Enrollment in a Phase II Clinical Trial in Solid Tumors. A Newly Granted Patent for Combretastatin A4P (CA4P). OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases, today reported operational and financial results for the first quarter ended March 31, 2006.
